DEF: Onconetix Seeks Shareholder Approval for Key Financings, Board Changes

Onconetix, Inc. calls for its Annual Meeting to approve significant private placement financings, elect new directors, and ratify its independent auditor.

Summary

• Onconetix, Inc. (the Company) will hold its Annual Meeting on December 5, 2025, to vote on five key proposals.
• Shareholders are asked to re-elect Thomas Meier and elect Sarah Romano as Class I directors for a three-year term expiring at the 2028 Annual Meeting.
• Approval is sought for the issuance of up to 4,424,080 shares of Common Stock upon conversion of Series D Preferred Stock and up to 4,362,827 shares upon exercise of Series D Warrants, stemming from a $12.9 million private placement that closed on September 22, 2025.
• Shareholders must also approve the issuance of up to 2,025,223 shares of Common Stock upon conversion of Series E Preferred Stock and up to 2,025,223 shares upon exercise of Series E Warrants, from a $6.25 million private placement that closed on October 1, 2025.
• These PIPE proposals require shareholder approval under Nasdaq Listing Rule 5635(a) because the potential issuance of Common Stock exceeds 20% of the Company's outstanding voting power and shares.
• The Company also seeks to ratify the appointment of MaloneBailey, LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2025.
• An Adjournment Proposal is included to allow for additional proxy solicitation if votes are insufficient for the other proposals.
• The Board unanimously recommends a 'FOR' vote on all proposals.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While the Company successfully raised significant capital through PIPE financings, the necessity for shareholder approval for already-closed transactions, coupled with the risk of losing anti-dilution benefits if approval is not granted, introduces uncertainty. Furthermore, the extensive management turnover, past financial irregularities involving a former CEO, and identified material weaknesses in internal controls, along with a 'going concern' opinion from a previous auditor, highlight significant operational and governance challenges. The new board appointments and clawback policy are positive steps, but the underlying issues warrant caution.

Positives

• Successfully secured approximately $12.9 million through Series D PIPE Financing and $6.25 million through Series E PIPE Financing, providing crucial capital for ongoing business needs and growth strategy.
• Nomination of Sarah Romano, an experienced public company CFO and certified accountant, is expected to bring valuable financial acumen and public company experience to the Board and Audit Committee.
• Re-election of Thomas Meier, an internationally recognized scientist with extensive experience in clinical research related to orphan diseases, continues valuable expertise and strategic insight to the Company's operations.
• The Board has established a Compensation Recovery Policy (clawback policy) to recover erroneously awarded incentive compensation, aligning with Section 10D of the Securities Exchange Act of 1934 and Nasdaq listing standards.

Negatives

• Failure to obtain shareholder approval for the Series D and Series E PIPE Proposals would prevent the Company from honoring anti-dilution adjustments below specified floor prices ($3.6896 for Series D, $3.8576 for Series E), potentially impacting future capital raising and significantly impairing operations.
• The Company's former auditor, EisnerAmper LLP, resigned effective October 15, 2024, and their audit report for 2023 contained an explanatory paragraph regarding the Company's ability to continue as a going concern.
• Management identified several material weaknesses in internal controls for the fiscal year ended December 31, 2024, including inadequate segregation of duties for cash disbursements, ineffective risk assessment, insufficient precision in controls, and lack of accounting resources.
• An administrative oversight led to the untimely filing of Form 4 reports for Christian Brühlmann and Ralph Schiess in December 2024.
• An Audit Committee review in 2023 identified approximately $363,000 in personal expenditures of the Company's former CEO and an accounting employee, for which a full reserve was recorded after recovering approximately $159,000.

Risks

• Failure to obtain stockholder approval for the Series D and Series E PIPE Proposals could materially adversely affect the Company's future ability to raise equity or debt capital from third parties on attractive terms, if at all, and risks significantly impairing operations, assets, and ongoing viability.
• The inability to exercise Series D and Series E Warrants at adjusted exercise prices due to lack of stockholder approval may impact the Company's ability to receive net proceeds from cash exercises of such warrants.
• The Company will incur additional costs and expenses associated with calling subsequent stockholder meetings semi-annually if PIPE approvals are not obtained, which could materially adversely impact funding for operations and business plans.
• The existence of financial and personal interests of one or more directors may create conflicts of interest in recommending proposals to stockholders.
• The Company faces risks related to financial and product commercialization, as noted by the Board in its risk oversight process.

Future Outlook

The Company's ability to successfully implement its business plans and growth strategy and ultimately maximize value for stockholders is dependent upon its ability to raise capital and satisfy ongoing business needs. Failure to approve the Series D and Series E PIPE Proposals would significantly and adversely affect these capabilities, potentially impairing operations and future capital raising efforts. The Company is committed to seeking stockholder approval for these financings, with plans for subsequent meetings if initial approval is not obtained.

Management Comments

• "The Onconetix Board has unanimously determined and resolved that the Director Election Proposal, the Series D PIPE Proposal, the Series E PIPE Proposal, and the Auditor Ratification Proposal are advisable and fair to, and in the best interests of, Onconetix and its stockholders."
• "Accordingly, the Onconetix Board unanimously recommends that Onconetix stockholders vote FOR each of the foregoing proposals."
• "Our ability to successfully implement our business plans and growth strategy and ultimately maximize value for our stockholders is dependent upon our ability to raise capital and satisfy our ongoing business needs and growth strategy, which we believe would be significantly and adversely affected if our stockholders do not approve the Series D PIPE Proposal."
• "Our Audit Committee and Board believe that stability and continuity in the Company’s auditor is important as we advance our business plan."

Industry Context

The biotech and life sciences industry often relies heavily on capital raises, including private placements like PIPE financings, to fund research, development, and operational needs. The requirement for shareholder approval for significant dilutive events (exceeding 20% of outstanding shares) is a standard Nasdaq listing rule, reflecting a balance between company financing needs and shareholder protection. The frequent changes in executive leadership and identified material weaknesses in internal controls, coupled with a 'going concern' explanatory paragraph from a former auditor, suggest challenges in operational stability and financial oversight, which are critical for investor confidence in the volatile biotech sector.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the Company's performance against global benchmarks. However, the need for significant PIPE financings and the associated dilution is common for early-stage or growth-focused biotech companies.
• The identified material weaknesses in internal controls and the 'going concern' opinion from a former auditor are below industry best practices for financial reporting and corporate governance, indicating areas requiring substantial improvement compared to established public companies in the sector.

Management Changes

Corporate Governance

Related Party Transactions

• On January 23, 2024, the Company issued a non-convertible debenture in the principal sum of $5.0 million to Altos Ventures, a stockholder of the Company, with an interest rate of 4.0% per annum.
• During 2023, an Audit Committee review identified approximately $363,000 in personal expenditures of the Company's former CEO and an accounting employee from 2022 and the first three quarters of 2023. Approximately $159,000 was recovered, and a full reserve was recorded for the remaining amount, resulting in a net related party receivable balance of $0 as of December 31, 2023. No such transactions occurred in 2024.
• A short-term lease in Palm Beach, Florida, from May 1, 2022, to April 30, 2023, for approximately $14,000 per month, was personally guaranteed by the Company's former CEO. Rent expense of approximately $51,000 was incurred in 2023.
• Thomas Meier, a director, provides consulting services to Proteomedix through an agreement effective January 4, 2024, with approximately $58,000 in related expenses recorded in 2024.
• On February 28, 2025, the Company entered into a consulting agreement with James Sapirstein, former Executive Chairman and Board member, for compensation at $400 per hour for up to twenty hours per week.

Stakeholder Impact

• **Shareholders**: Potential significant dilution from the Series D and E PIPE financings if approved, but also critical capital infusion to support the Company's operations and growth. Failure to approve could severely impact the Company's viability and future capital raising, negatively affecting shareholder value. The identified material weaknesses and past financial irregularities may erode investor confidence.
• **Investors (PIPE)**: Their ability to fully benefit from anti-dilution adjustments on their Series D and E Preferred Stock and Warrants is contingent on shareholder approval. Failure to approve could reduce the value of their investment.
• **Employees**: The Company's ability to fund operations and advance business plans, which is dependent on capital raises, directly impacts job security and growth opportunities. Management changes may create uncertainty.
• **Management**: The Interim CEO and CFO, Karina Fedasz, is tasked with navigating these critical shareholder approvals and addressing the identified internal control weaknesses. The Board's unanimous recommendation indicates strong internal support for the proposals.
• **Auditors**: MaloneBailey's appointment and ratification are crucial for ensuring proper financial oversight and addressing the 'going concern' issues and material weaknesses identified by the previous auditor.

Next Steps

• Hold the Annual Meeting of Stockholders on December 5, 2025, to vote on the proposed matters.
• If the Series D PIPE Proposal is not approved, call another stockholder meeting no later than March 1, 2026, and semi-annually thereafter until approval is obtained.
• If the Series E PIPE Proposal is not approved, call another stockholder meeting no later than March 10, 2026, and semi-annually thereafter until approval is obtained.
• The Board intends to appoint Sarah Romano to the Audit Committee if she is elected as a director.
• Continue to address and remediate the identified material weaknesses in internal controls and financial reporting.

Key Dates

Recommendation

The filing presents a mixed bag of critical developments. On one hand, Onconetix has successfully secured substantial capital through two PIPE financings, which are essential for its ongoing operations and growth strategy, especially given the previous 'going concern' opinion. The proposed board changes, particularly the addition of a seasoned CFO, are positive for corporate governance. However, the need for shareholder approval for these already-closed financings, with the risk of losing anti-dilution benefits if not approved, introduces significant uncertainty and potential for substantial dilution. The extensive management turnover, past financial irregularities involving a former CEO, and the identified material weaknesses in internal controls are serious concerns that indicate ongoing operational and governance challenges. Investors should hold, awaiting the outcome of the shareholder vote and further clarity on the Company's ability to remediate its internal control deficiencies and execute its business plan effectively. The potential for significant dilution and the historical governance issues warrant caution, despite the necessary capital infusion.

Keywords

Onconetix, Proxy Statement, Annual Meeting, PIPE Financing, Series D Preferred Stock, Series E Preferred Stock, Warrants, Nasdaq Listing Rule 5635, Shareholder Approval, Corporate Governance, Director Election, Auditor Ratification, Capital Raise, Dilution, Material Weaknesses, SEC Filing